Drug intelligence / Profile preview

butaphosphan + cyanocobalamin

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Subcutaneous
01

Overview

Butaphosphan + cyanocobalamin is a veterinary combination drug marketed under the brand name Catosal. It was originally developed by Bayer Animal Health and is now part of the Elanco portfolio following Elanco's acquisition of Bayer's animal health business. The formulation contains butaphosphan, an organic phosphorus compound, and cyanocobalamin (Vitamin B12). It functions as a metabolic stimulant, roborant, and tonic, primarily used in livestock such as cattle, sheep, and pigs. Butaphosphan serves as a source of phosphorus and promotes gluconeogenesis, while cyanocobalamin acts as a vital cofactor in the tricarboxylic acid cycle and supports red blood cell production. The drug is indicated for metabolic disorders, phosphorus deficiency, subclinical ketosis in dairy cattle, and to support animals during high-stress periods like pregnancy and the postpartum period. It is administered via intravenous, intramuscular, or subcutaneous injection.

Brand names
Catosal
Other names
butafosfan + cyanocobalaminbutaphosphan + vitamin B12butafosfan + vitamin B12
02

Targets

MTR (Methionine synthase)MMUT (Methylmalonyl-coenzyme A mutase)

Beyond the preview

Go deeper on butaphosphan + cyanocobalamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on butaphosphan + cyanocobalamin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call